Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.

Lisa H LancasterJonathan GoldinMatthias TrampischGrace Hyun J Kim Jonathan IlowiteLawrence HomikDavid L HotchkinMitchell KayeChristopher J RyersonNesrin MogulkocCraig S Conoscenti

Published in: The open respiratory medicine journal (2020)

Exploratory data suggest that in patients with IPF, 6 months' treatment with nintedanib was associated with a numerically smaller degree of fibrotic change in the lungs and reduced FVC decline versus placebo. These data support previous findings that nintedanib slows the progression of IPF.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
electronic health record
big data
high resolution
data analysis
clinical trial
machine learning
rheumatoid arthritis
randomized controlled trial
combination therapy
systemic sclerosis
artificial intelligence
mass spectrometry
double blind
open label
phase iii